A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Renaissance Technologies LLC holds 59,600 shares of VRDN stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,600
Previous 247,600 75.93%
Holding current value
$1.16 Million
Previous $3.22 Million 57.93%
% of portfolio
0.0%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$12.16 - $23.33 $2.29 Million - $4.39 Million
-188,000 Reduced 75.93%
59,600 $1.36 Million
Q2 2024

Aug 09, 2024

SELL
$11.6 - $17.26 $163,560 - $243,366
-14,100 Reduced 5.39%
247,600 $3.22 Million
Q1 2024

May 13, 2024

BUY
$17.09 - $23.82 $4.24 Million - $5.91 Million
248,300 Added 1852.99%
261,700 $4.58 Million
Q4 2023

Feb 13, 2024

SELL
$11.12 - $22.5 $576,016 - $1.17 Million
-51,800 Reduced 79.45%
13,400 $292,000
Q3 2023

Nov 14, 2023

SELL
$15.16 - $24.7 $163,728 - $266,760
-10,800 Reduced 14.21%
65,200 $1 Million
Q2 2023

Aug 11, 2023

BUY
$22.57 - $29.67 $907,314 - $1.19 Million
40,200 Added 112.29%
76,000 $1.81 Million
Q1 2023

May 12, 2023

BUY
$25.04 - $37.6 $896,432 - $1.35 Million
35,800 New
35,800 $911,000
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $1.09 Million - $2.59 Million
101,600 New
101,600 $2.08 Million
Q2 2021

Aug 13, 2021

SELL
$14.34 - $18.67 $189,861 - $247,190
-13,240 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$15.5 - $24.93 $205,220 - $330,073
13,240 New
13,240 $221,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $776M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.